医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Verdezyne Signs Distribution Agreement with Connell Bros.

2016年03月09日 AM08:00
このエントリーをはてなブックマークに追加


 

CARLSBAD, Calif. & SAN FRANCISCO

Verdezyne, Inc., a synthetic biology company producing biobased chemicals, and Connell Bros. Co. LLC (CBC), the largest marketer and distributor of specialty chemicals in the Asia-Pacific region, announced an agreement for sales and distribution of Verdezyne’s BIOLON™ DDDA (biobased dodecanedioic acid or “DC12”). BIOLON™ DDDA will be produced at Verdezyne’s commercial-scale plant in Malaysia and will be distributed in 17 countries throughout Asia-Pacific, including China, Japan and South Korea. The agreement assures CBC of access to more than 10% of the expected plant capacity.

Verdezyne’s BIOLON™ DDDA is produced more sustainably than traditional petroleum-derived intermediate chemicals and will be used to make a variety of end-user products including automotive parts, toothbrush bristles, cosmetics, and fragrances.

“This agreement with CBC reflects the strong interest in high quality renewable chemicals such as our BIOLON™ DDDA,” said E. William Radany, Ph.D., president and CEO of Verdezyne. “As one of the largest and most respected distributors of specialty chemicals in the Asia-Pacific region, CBC is a strong partner for us. We are sure this agreement marks the beginning of a long and mutually-beneficial relationship.”

Verdezyne’s plant, expected to be completed in 2017, is anticipated to have the capacity to produce up to 9,000 metric tons of diacids including BIOLON™ DDDA annually.

“Verdezyne presented us with a very strong value proposition,” commented Scott Graddy, vice president, CBC. “We anticipate a strong demand for BIOLON™ DDDA from our customers in Asia-Pacific. We are very pleased to have reached this agreement with Verdezyne and we look forward to distributing BIOLON™ DDDA throughout the region.”

For samples, orders or more information about Verdezyne’s BIOLON DDDA, please contact:

About Verdezyne

Verdezyne is a synthetic biology company offering biobased chemicals developed using proprietary metabolic pathway engineering tools. The company’s first product, BIOLON™ DDDA, earned the USDA Certified Biobased Product label, and is available worldwide. Current investors in Verdezyne include BP Ventures, DSM Venturing B.V., OVP Venture Partners, Monitor Ventures, and Sime Darby. For more information, visit www.verdezyne.com or connect with the company on TwitterLinkedIn or Facebook.

About Connell Bros. Co.

Founded in 1895, Connell Bros. Co. LLC is one of the Wilbur-Ellis family of companies and is the largest marketer and distributor of specialty chemicals and ingredients in Asia-Pacific with a keen focus on technical service, customer support, and environmental, health, and safety. Connell Brothers provides complete supply chain management from transportation, documentation, warehousing, and sales and distribution in 17 countries and in 47 offices located throughout Asia-Pacific. For more information, please visit www.connellbrothers.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160308005267/en/

CONTACT

Verdezyne Media Contacts:
Verdezyne, Inc.
Aida Yodites,
760-707-5200
Corporate Communications
ayodites@verdezyne.com
or
Sparkpr
Bill
Douglass, 646-504-0890
bdouglass@sparkpr.com
or
Connell
Bros. Co. Media Contact:

Hong Kong Media Contact:
Mandy
Weih, + 852.2969.2730
mandy.weih@wecocbc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果